Preparation method of empagliflozin and metformin sustained release tablets

By using aminoalkyl methacrylate copolymer E-coating technology, the problem of unstable empagliflozin metformin sustained release tablets during placement is solved, and the long-term stability and production efficiency of the drug are improved, ensuring that The quality control effect and stability of the drug.

CN118986908APending Publication Date: 2024-11-22SHANDONG LINUO KEFENG PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411093097.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing empagliflozin metformin sustained release double-layer tablets have unstable problems during placement, mainly due to the interaction caused by direct contact between the two main drugs.

Method used

Using aminoalkyl methacrylate copolymer E-type coating technology, engagliflozin is mixed with diluent and fluidized coating is carried out to avoid contact between the main drug at the interface of the double-layer tablet, and prepared by fluidization method Engaliflozin coats the total mixing granules to ensure the uniformity and stability of the drug.

Benefits of technology

Effectively avoid direct contact between engagliflozin and metformin, improve the long-term placement stability of the drug, ensure the quality control effect and production efficiency of the drug, and improve the light and thermal stability of the drug through improved coating materials and Water soluble.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004987124860000071
    Figure BDA0004987124860000071
  • Figure BDA0004987124860000091
    Figure BDA0004987124860000091
  • Figure BDA0004987124860000092
    Figure BDA0004987124860000092
Patent Text Reader

Abstract

The invention belongs to the technical field of pharmaceutical preparations, and relates to a preparation method of empagliflozin and metformin sustained release tablets. Comprising the following steps: preparing metformin sustained-release total mixed particles, preparing empagliflozin coated total mixed particles, and carrying out double-layer tablet pressing on the metformin sustained-release total mixed particles and the empagliflozin coated total mixed particles, wherein in the preparation of empagliflozin coating total mixed particles, the methacrylic acid aminoalkyl ester copolymer E type is adopted for coating. According to the preparation method disclosed by the invention, the contact of the empagliflozin and the metformin as two main drugs can be effectively avoided, so that the instability caused by interaction due to direct contact of the main drugs during the placement period is avoided, and the stability is good after long-term placement; meanwhile, the quality control effect is improved, and the production efficiency of the empagliflozin and metformin sustained release tablets is guaranteed.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of pharmaceutical preparations and relates to a method for preparing empagliflozin metformin sustained-release tablets. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Empagliflozin is an emerging class of hypoglycemic drugs, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, which can block the reabsorption of glucose in the kidneys and excrete excess glucose into the body, thereby achieving the effect of lowering blood sugar. Moreover, this hypoglycemic effect is independent of β-cell function and insulin resistance. Metformin hydrochloride is a common initial treatment for type 2 diabetes. It can reduce the production of glycogen and the absorption of glucose in the small intestine, and can increase insulin sensitivity by increasing the uptake and utilization of glucose by peripheral tissues. The two drugs complement each other in terms of pharmacological mechanisms.

[0004] At present, the sustained-release preparations of empagliflozin metformin include sustained-release granules, immediate-release granules and double-layer tablets. Among them, the double-layer tablets are prepared by wet granulation process to prepare metformin hydrochloride granules and empagliflozin granules respectively, and then directly compressed after mixing with external excipients; compared with other sustained-release preparations, the preparation method of the double-layer tablets is simpler and the production efficiency is higher. However, the inventors found that the empagliflozin metformin sustained-release double-layer tablets prepared by the existing method have the problem of instability during the placement process. Summary of the invention

[0005] In order to solve the shortcomings of the prior art, the purpose of the present invention is to provide a method for preparing empagliflozin metformin sustained-release tablets. The preparation method of the present invention can effectively avoid the contact between the two main drugs, empagliflozin and metformin, thereby avoiding the instability caused by the interaction between the main drugs due to direct contact during storage, and the long-term storage stability is good; at the same time, the quality control effect is increased to ensure the production efficiency of empagliflozin metformin sustained-release tablets.

[0006] In order to achieve the above object, the technical solution of the present invention is:

[0007] In the first aspect, a method for preparing empagliflozin metformin sustained-release tablets comprises the preparation of metformin sustained-release mixed granules, the preparation of empagliflozin coated mixed granules, and double-layer tablet compression of metformin sustained-release mixed granules and empagliflozin coated mixed granules; wherein, in the preparation of empagliflozin coated mixed granules, aminoalkyl methacrylate copolymer type E is used for coating.

[0008] In the process of preparing the empagliflozin coated total mixed granules of the present invention, the coating can effectively isolate empagliflozin from the external environment, so that in the process of pressing the double-layer tablets, the contact between empagliflozin and metformin hydrochloride at the interface of the double-layer tablets can be effectively avoided, and the instability caused by the direct contact and interaction between the two main drugs during storage can be avoided, and the long-term storage stability is good.

[0009] At the same time, there are many gastric soluble coating materials, such as hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, etc. The present invention selects aminoalkyl methacrylate copolymer type E for coating in the preparation of empagliflozin coated total mixed particles, which can more effectively isolate moisture, prevent moisture penetration during long-term storage, and improve the stability of the drug.

[0010] In the coating process of the prior art, empagliflozin is directly added to the coating liquid, and then the coating liquid is sprayed for coating; however, the loss of the suspension during the spraying process leads to inaccurate control of the empagliflozin dosage; empagliflozin is suspended in the coating liquid, and stratification may occur during the spraying process, resulting in unqualified empagliflozin content uniformity in the tablets; the spray gun may be clogged during the suspension coating process, resulting in loss of empagliflozin raw materials in the suspension.

[0011] Therefore, in the preparation of the empagliflozin coated total mixed granules of the present invention, the empagliflozin and the diluent starch are evenly mixed by a fluidization method, the mixed material is kept fluidized and a solution of aminoalkyl methacrylate copolymer type E is sprayed into it for coating and granulation, and then the granulated particles are evenly mixed with the added excipients to obtain the empagliflozin coated total mixed granules.

[0012] The present invention uses a fluidized method to mix empagliflozin and a diluent (to ensure uniform dispersion of empagliflozin) uniformly before coating, thereby avoiding the problem of uneven distribution of empagliflozin and unqualified content uniformity caused by stratification of the coating liquid during the coating process of the empagliflozin suspension. In addition, the coating method can more effectively avoid contact between empagliflozin and metformin hydrochloride.

[0013] In a second aspect, an empagliflozin metformin sustained-release tablet is obtained by the preparation method described in the first aspect of the present invention.

[0014] The beneficial effects of the present invention are:

[0015] 1. The present invention adopts a coating method in the preparation of empagliflozin particles, especially an empagliflozin powder coating method, which can effectively avoid the contact between empagliflozin and metformin hydrochloride at the interface of the double-layer tablet, and can also avoid the instability caused by the direct contact and interaction between the two main drugs during storage, and has good long-term storage stability.

[0016] 2. In the process of preparing empagliflozin particles of the present invention, the coating material used is aminoalkyl methacrylate copolymer type E, which is a pH-sensitive coating material with good light and heat stability; and can quickly disintegrate and dissolve empagliflozin in a low pH environment; it has good water barrier properties, and can more effectively isolate moisture than ordinary gastric-soluble coating materials such as hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, etc., to prevent moisture penetration during long-term storage and improve the stability of the drug; it has good water solubility, and the coating solvent is water, which can prevent environmental pollution caused by organic solvent coating.

[0017] 3. In the process of preparing empagliflozin particles of the present invention, a fluidized method is used to evenly mix empagliflozin and a diluent, and then the coating liquid is sprayed into the mixture for powder coating, thereby avoiding the problem of uneven distribution of empagliflozin and unqualified content uniformity caused by stratification of the coating liquid during the coating process of the empagliflozin suspension.

[0018] 4. In the process of preparing empagliflozin particles of the present invention, the compressibility and fluidity of the particles can be improved by powder coating, and the dissolution rate of empagliflozin can also be improved.

[0019] 5. The total mixed granules prepared by coating the empagliflozin powder of the present invention can be tableted according to the content determination, and the dosage is accurately controlled, thus avoiding the problem of uncontrollable dosage caused by liquid spraying of empagliflozin.

[0020] 6. The empagliflozin coated mixed granules and metformin sustained-release mixed granules of the present invention can be prepared simultaneously and then pressed into double-layer tablets, which greatly improves the production efficiency. DETAILED DESCRIPTION

[0021] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0022] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit exemplary embodiments according to the present invention. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0023] In view of the fact that the empagliflozin metformin sustained-release bilayer tablets prepared by the existing method are unstable during the storage process, the present invention provides a method for preparing the empagliflozin metformin sustained-release tablets.

[0024] A typical embodiment of the present invention provides a method for preparing empagliflozin metformin sustained-release tablets, including the preparation of metformin sustained-release mixed granules, the preparation of empagliflozin coated mixed granules, and double-layer tablet compression of metformin sustained-release mixed granules and empagliflozin coated mixed granules; wherein, in the preparation of empagliflozin coated mixed granules, aminoalkyl methacrylate copolymer type E is used for coating.

[0025] In some embodiments, in the preparation of empagliflozin coated mixed granules, empagliflozin and the diluent are mixed evenly by a fluidization method, the mixed material is kept fluidized and a solution of aminoalkyl methacrylate copolymer type E is sprayed in for coating and granulation, and then the granulated particles are mixed evenly with the added excipients to obtain empagliflozin coated mixed granules.

[0026] Specifically, the mass of empagliflozin is 2 to 8% of the total mass of the empagliflozin coated mixed granules.

[0027] Specifically, the diluent is starch.

[0028] Specifically, the mass of the diluent is 2 to 15% of the total mass of the empagliflozin coated mixed granules.

[0029] Specifically, the mass of aminoalkyl methacrylate copolymer type E is 10 to 30% of the total mass of the empagliflozin coated mixed granules.

[0030] Specifically, the solution of aminoalkyl methacrylate copolymer type E contains a plasticizer. Adding a plasticizer can reduce the viscosity of the solution, improve fluidity, make the coating smoother, and increase the uniformity of subsequent mixing; secondly, the plasticizer can make the aminoalkyl methacrylate copolymer type E softer, avoid problems such as rupture or cracking during the coating process, thereby better avoiding the contact between empagliflozin and metformin; thirdly, the plasticizer can make the surface of the coating material more wear-resistant, avoid damage to the coating layer during subsequent mixing, and further avoid the contact between empagliflozin and metformin. More specifically, the plasticizer is one or more of triethyl citrate, polyethylene glycol 6000, tributyl citrate, dibutyl sebacate, etc., preferably triethyl citrate. More specifically, the mass of the plasticizer is 2 to 6% of the total mass of the total mixed particles of the empagliflozin coating.

[0031] Specifically, the mass of the added excipients is 62.5-97% of the total mass of the total mixed granules of the empagliflozin coating. More specifically, the added excipients are fillers, disintegrants and lubricants. More specifically, the filler is one or more of microcrystalline cellulose, lactose, starch, calcium hydrogen phosphate, etc., preferably microcrystalline cellulose. More specifically, the mass of the filler is 60-85% of the total mass of the total mixed granules of the empagliflozin coating. More specifically, the disintegrant is one or more of cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose, and sodium carboxymethyl starch, preferably cross-linked polyvinylpyrrolidone and cross-linked sodium carboxymethyl cellulose. More specifically, the mass of the disintegrant is 2-8% of the total mass of the total mixed granules of the empagliflozin coating. More specifically, the lubricant is one or more of colloidal silicon dioxide, magnesium stearate, sodium stearyl fumarate, etc., preferably magnesium stearate. More specifically, the mass of the lubricant is 0.5-4% of the total mass of the total mixed granules of the empagliflozin coating.

[0032] Metformin sustained-release total mixed granules can be prepared by any method for preparing granules of metformin sustained-release tablets or granules of metformin sustained-release layers in the prior art. In some embodiments, metformin or metformin hydrochloride is wet granulated with a binder, and then a sustained-release skeleton material and a lubricant are added and mixed uniformly to obtain metformin sustained-release total mixed granules.

[0033] Specifically, based on metformin hydrochloride, the mass of metformin or metformin hydrochloride is 60-85% of the total metformin sustained-release mixed granules.

[0034] Specifically, the binder is one or more of hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, cross-linked polyvinylpyrrolidone, etc., preferably sodium carboxymethyl cellulose and hydroxypropyl methylcellulose.

[0035] Specifically, the mass of the binder is 2-7% of the total mixed particles of metformin sustained-release.

[0036] Specifically, the sustained-release matrix material is one or more of hydroxypropyl methylcellulose, polyethylene oxide, methyl cellulose, povidone, etc., preferably hydroxypropyl methylcellulose and polyethylene oxide.

[0037] Specifically, the mass of the sustained-release matrix material is 15-30% of the total metformin sustained-release mixed particles.

[0038] Specifically, the lubricant includes one or more of colloidal silicon dioxide, magnesium stearate, talc, etc., preferably colloidal silicon dioxide and magnesium stearate.

[0039] Specifically, the mass of the lubricant is 0.5-4% of the metformin sustained-release mixed granules.

[0040] In some embodiments, when the metformin sustained-release mixed granules and the empagliflozin coated mixed granules are compressed into double-layer tablets, the mass ratio of the metformin sustained-release mixed granules to the empagliflozin coated mixed granules is 200-1000:1250-1600.

[0041] In some embodiments, the bi-layer tablets are compressed and then coated with a gastric soluble film coating premix.

[0042] Another embodiment of the present invention provides an empagliflozin metformin sustained-release tablet obtained by the preparation method described in the first aspect of the present invention.

[0043] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below in combination with specific embodiments and comparative examples.

[0044] Example 1

[0045] (I) Prescription composition

[0046]

[0047]

[0048] (II) Preparation process:

[0049] 1. Empagliflozin layer:

[0050] ① Preparation of coating solution: dissolve the prescribed amount of coating powder aminoalkyl methacrylate copolymer type E and plasticizer triethyl citrate in an appropriate amount of purified water to prepare a solution with a coating powder solid content of 10%, and set aside.

[0051] ② Add the prescribed amount of empagliflozin and starch into the fluidized bed coating granulator and turn on the fan to control the air volume to 1000-2000m 3 / h, mix for 15 minutes, turn on the heating, set the inlet air temperature to 55-65℃, when the material temperature reaches above 40℃, turn on the peristaltic pump and liquid adding spray gun, control the atomization pressure to 0.1-0.3MPa, the spray speed to 150g-300g / min, and the material temperature to 40-50℃. After the spraying is completed, continue to dry to a moisture content of ≤5%. The dry particles are sieved through a 30-mesh sieve, and the sieve-under material is taken for later use.

[0052] ③ Add the sieved dry granules into a universal mixer, add microcrystalline cellulose 302, cross-linked polyvinylpyrrolidone, and magnesium stearate converted according to the weight of the dry granules, and mix for 10 minutes at a speed of 10 rpm on the main shaft and 10 rpm on the secondary shaft to obtain empagliflozin immediate-release coated mixed granules.

[0053] 2. Metformin layer:

[0054] ① Premixing: Add metformin hydrochloride and sodium carboxymethylcellulose into a wet mixing granulator, with the stirring blade speed at 120 rpm and the cutting blade speed at 300 rpm, and mix for 5 minutes;

[0055] ② Granulation: Use purified water with a weight of 15% of the total weight of the premixed material as a wetting agent, add it into the wet granulation mixer to make soft material, the stirring paddle speed is 150rpm, the cutting knife speed is 1200rpm, the wetting agent addition rate is 60g / min, the atomization pressure is 0.04MPa, and continue granulation for 3min after the wetting agent is added. Pass the soft material through a 4*4mm square hole crushing and granulating machine for wet granulation;

[0056] ③ Drying: Fluidized bed air inlet temperature 50℃, air volume 60m 3 / h, add wet granules after preheating for 10 minutes, the material temperature does not exceed 40℃, and dry to moisture ≤4%.

[0057] ④ Granulation: Granulate through a 1.0mm round hole crusher.

[0058] ⑤ Total mixing: Add the dry granules into a universal mixer, add hydroxypropyl methylcellulose, silicon dioxide, and magnesium stearate converted according to the weight of the dry granules, mix at 10 rpm on the main shaft and 10 rpm on the secondary shaft for 10 min to obtain metformin sustained-release total mixed granules.

[0059] 3. Tableting:

[0060] Use 20.3mm*10.8mm oval punch, and press tablets according to the content. The first layer of tablets is metformin layer with hardness of 60-100N, and the second layer of tablets is dapagliflozin layer. The hardness of double-layer tablets is 250-350N.

[0061] 4. Coating

[0062] Prepare 1.5 times the amount of coating liquid with a solid content of 15%. Pour the tablet core into the coating pan, with an air inlet temperature of 50°C, a fan frequency of 60%, a coating pan speed of 3.5rpm, and preheat for at least 5 minutes until the tablet bed temperature reaches 35°C before spraying. Increase the coating pan speed to 10rpm, control the tablet bed temperature within the range of 35-40°C, the peristaltic pump speed to 2.5-3.5rpm, the atomization pressure to 0.4MPa, the flattening pressure: 0.4MPa, stop spraying when the coating weight increases to about 2%, and dry for 5 minutes.

[0063] (III) Properties of Empagliflozin Coated Granules

[0064] Particle size distribution of empagliflozin coated mixed granules

[0065]

[0066] Powder properties of empagliflozin coated granules

[0067]

[0068] Double-layer tablet hardness test results - friability

[0069]

[0070]

[0071] The above results show the properties of empagliflozin coated mixed particles: the particles have good fluidity and good compressibility.

[0072] (IV) Comparison of dissolution curves

[0073] Table 1 Comparison of dissolution curves of empagliflozin (pH 6.8, specification 25mg / 1000mg)

[0074] Comparison of metformin dissolution curves (pH 6.8, specification 25mg / 1000mg)

[0075]

[0076] The dissolution curves of dapagliflozin and metformin in the pH 6.8 medium (main medium) of the self-made product 1 prepared according to Example 1 of the present invention and the reference preparation were similar.

[0077] (V) Comparison of key test items in stability test

[0078] 1. Comparison between self-made products and reference preparations

[0079] The stability of the self-made product 1 obtained in Example 1 was compared with that of the reference preparation through a stability test. The stability test adopted accelerated test conditions, i.e., 40°C ± 2°C, 75% ± 5% RH, and the inspection period was 6 months. The comparison of the key project test results is as follows:

[0080] Stability test results comparison table (Specification 25mg / 1000mg)

[0081]

[0082]

[0083] From the above test results, it can be seen that the uniformity of the empagliflozin content in the sample prepared by Example 1 is good. The results of the 6-month accelerated test show that the self-made product 1 has good stability, and the test results of various test indicators are comparable to those of the reference preparation.

[0084] Example 2

[0085] (I) Prescription process

[0086]

[0087]

[0088] (II) Preparation process:

[0089] 1. The preparation of the empagliflozin layer is the same as in Example 1.

[0090] 2. Metformin layer:

[0091] ① Prepare a hydroxypropyl methylcellulose solution as an adhesive. Add purified water to the hydroxypropyl methylcellulose added in the form of a solution to prepare an 8% hydroxypropyl methylcellulose solution for use as an adhesive.

[0092] ② Premixing and granulation: Add metformin hydrochloride and internally added hydroxypropyl methylcellulose to a high shear wet mixing granulator, and premix at a shear speed of 600 rpm, a stirring speed of 150 rpm, and a mixing time of 5 min. Soft material preparation: Turn on the peristaltic pump, and prepare the soft material at a shear speed of 1500 rpm, a stirring speed of 120 rpm, an atomization pressure of 0.8-1.4 bar, and a peristaltic pump speed of 10-20 rpm. Post-granulation: Continue post-granulation at a shear speed of 600 rpm, a stirring speed of 120 rpm, and a mixing time of 3 min.

[0093] ③ Wet granulation: Open the discharge port of the high shear wet mixing granulator, and pass the prepared soft material through a granulation screen with a stainless steel square hole of 4×4mm aperture for wet granulation.

[0094] ④ Drying: Use fluidized bed, with air inlet temperature of 60±10℃ and air volume of 1000±500m 3 / h, preheat the empty machine to exhaust air temperature ≥45℃, dry the granules after wet granulation until the moisture content is ≤4%, then stop drying. Transfer the dried granules to the lifting dry granulator and use a stainless steel screen with a pore size of 1.2mm for dry granulation.

[0095] ⑤ Total mixing: According to the total weight of the dry granules, the additional materials polyoxyethylene and magnesium stearate are converted and weighed, and added to the mixer at a mixing speed of 10 rpm and a mixing time of 10 min to obtain metformin sustained-release total mixed granules.

[0096] 3. Tableting and coating process are the same as in Example 1

[0097] (III) Properties of Empagliflozin Coated Granules

[0098] Particle size distribution of empagliflozin coated mixed granules

[0099]

[0100] Powder properties of empagliflozin coated mixed granules

[0101]

[0102] Double-layer tablet hardness test results - friability

[0103]

[0104] The above results show the properties of empagliflozin coated mixed particles: the particles have good fluidity and good compressibility.

[0105] (IV) Comparison of dissolution curves

[0106] Table 1: Dissolution curve of empagliflozin (pH 6.8, specification 10mg / 1000mg)

[0107] Metformin layer dissolution curve (pH 6.8, specification 10mg / 1000mg) table

[0108]

[0109] The dissolution curves of empagliflozin and metformin in the pH 6.8 medium (main medium) of the self-made preparation 2 prepared according to Example 2 and the reference preparation were similar.

[0110] (V) Comparison of key test items in stability test

[0111] The stability of the self-made product 2 obtained in Example 2 was compared with that of the reference preparation through a stability test. The stability test adopted accelerated test conditions, i.e., 40°C ± 2°C, 75% ± 5% RH, and the inspection period was 6 months. The comparison of the key project test results is shown in the following table:

[0112] Stability test results comparison table (Specification 10mg / 1000mg)

[0113]

[0114]

[0115]

[0116] From the above test results, it can be seen that the uniformity of the empagliflozin content in the self-made product 2 prepared by Example 2 is good. The results of the 6-month accelerated test show that the self-made product 2 has good stability, and the test results of various test indicators are comparable to those of the reference preparation.

[0117] Comparative Example 1

[0118] A double-layer tablet was prepared according to the prescription and preparation method of Example 6 of patent CN107432869A, and the coating powder and coating process of Example 1 of the present invention were used to coat the double-layer tablet (the weight gain of the tablet after coating reached 2% of the weight of the double-layer tablet), to prepare sample 1.

[0119] Comparative Example 2

[0120] Sample 2 was prepared by adopting the same preparation process as Example 1, except that the powder coating material was replaced by hydroxypropyl methylcellulose from aminoalkyl methacrylate copolymer type E.

[0121] Comparative Example 3

[0122] The same preparation process as in Example 1 was adopted, except that the powder coating material was replaced by ethyl cellulose from aminoalkyl methacrylate copolymer type E to prepare sample 3.

[0123] The stability test adopts accelerated test conditions, i.e. 40℃±2℃, 75%±5%RH, and the inspection period is 6 months. The comparison of key project test results of self-made product 1, sample 1, sample 2, and sample 3 is shown in the following table:

[0124] Stability test results comparison table (Specification 12.5mg / 1000mg)

[0125]

[0126]

[0127] From the above results, it can be seen that the self-made product 1, sample 2 and sample 3 prepared by powder coating are superior to the sample 1 prepared by the prior art 2 in terms of relevant substances and dissolution after accelerated 6-month stability test; the test results of various key items of the self-made product 1 coated with methacrylate aminoalkyl copolymer E type powder for 6 months were not significantly different from those of 0 days, and were better than the test results of sample 1, sample 2 and sample 3, indicating that the present invention is feasible and the quality of the prepared samples is controllable and stable.

[0128] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A method for preparing empagliflozin metformin sustained-release tablets, characterized in that: The method includes the preparation of metformin sustained-release mixed granules, the preparation of empagliflozin coated mixed granules, and double-layer tablet compression of metformin sustained-release mixed granules and empagliflozin coated mixed granules; wherein, in the preparation of empagliflozin coated mixed granules, aminoalkyl methacrylate copolymer type E is used for coating.

2. The method for preparing the empagliflozin metformin sustained-release tablets according to claim 1, characterized in that: In the preparation of the empagliflozin coated total mixed granules, the empagliflozin and the diluent are mixed evenly by a fluidized method, the mixed material is kept fluidized and a solution of aminoalkyl methacrylate copolymer type E is sprayed in for coating and granulation, and then the granulated particles are mixed evenly with the added excipients to obtain the empagliflozin coated total mixed granules.

3. The method for preparing the empagliflozin metformin sustained-release tablets according to claim 2, characterized in that: The mass of empagliflozin is 2 to 8% of the total mass of the empagliflozin coated total mixed granules; Or, the diluent is starch; Or, the mass of the diluent is 2 to 15% of the total mass of the empagliflozin coated mixed granules; Or, the mass of aminoalkyl methacrylate copolymer type E is 10 to 30% of the total mass of the empagliflozin coated total mixed granules; Or, the solution of aminoalkyl methacrylate copolymer type E contains a plasticizer; preferably, the plasticizer is one or more of triethyl citrate, polyethylene glycol 6000, tributyl citrate, and dibutyl sebacate, preferably triethyl citrate; preferably, the mass of the plasticizer is 2 to 6% of the total mass of the empagliflozin coated total mixed particles.

4. The method for preparing the empagliflozin metformin sustained-release tablets according to claim 2, characterized in that: The mass of the added excipients is 62.5-97% of the total mass of the empagliflozin coated total mixed granules; preferably, the added excipients are fillers, disintegrants and lubricants; preferably, the filler is one or more of microcrystalline cellulose, lactose, starch, and calcium hydrogen phosphate, preferably microcrystalline cellulose; preferably, the mass of the filler is 60-85% of the total mass of the empagliflozin coated total mixed granules; preferably, the disintegrant is one or more of cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose, and sodium carboxymethyl starch, preferably cross-linked polyvinylpyrrolidone and cross-linked sodium carboxymethyl cellulose; preferably, the mass of the disintegrant is 2-8% of the total mass of the empagliflozin coated total mixed granules; preferably, the lubricant is one or more of colloidal silicon dioxide, magnesium stearate, and sodium stearyl fumarate, preferably magnesium stearate; preferably, the mass of the lubricant is 0.5-4% of the total mass of the empagliflozin coated total mixed granules.

5. The method for preparing the empagliflozin metformin sustained-release tablets according to claim 1, characterized in that: Metformin or metformin hydrochloride is wet granulated with a binder, and then a sustained-release skeleton material and a lubricant are added and mixed evenly to obtain metformin sustained-release total mixed granules.

6. The method for preparing the empagliflozin metformin sustained-release tablets according to claim 5, characterized in that: Calculated as metformin hydrochloride, the mass of metformin or metformin hydrochloride is 60 to 85% of the total metformin sustained-release mixed granules; Or, the binder is one or more of hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, and cross-linked polyvinylpyrrolidone, preferably sodium carboxymethyl cellulose or hydroxypropyl methylcellulose; Alternatively, the mass of the binder is 2-7% of the total mixed granules of metformin sustained-release.

7. The method for preparing the empagliflozin metformin sustained-release tablets according to claim 5, characterized in that: The sustained-release matrix material is one or more of hydroxypropyl methylcellulose, polyoxyethylene, methylcellulose, and povidone, preferably hydroxypropyl methylcellulose or polyoxyethylene; Or, the mass of the sustained-release matrix material is 15-30% of the total mixed granules of metformin sustained-release; Or, the lubricant includes one or more of colloidal silicon dioxide, magnesium stearate, and talc, preferably colloidal silicon dioxide or magnesium stearate; Alternatively, the mass of the lubricant is 0.5-4% of the metformin sustained-release mixed granules.

8. The method for preparing the empagliflozin metformin sustained-release tablets according to claim 1, characterized in that: In the double-layer tablet compression of metformin sustained-release total mixed granules and empagliflozin coated total mixed granules, the mass ratio of metformin sustained-release total mixed granules to empagliflozin coated total mixed granules is 200-1000:1250-1600.

9. The method for preparing the empagliflozin metformin sustained-release tablets according to claim 1, characterized in that: After compression, the double-layer tablets are coated with a gastric soluble film coating premix.

10. An empagliflozin metformin sustained-release tablet, characterized in that: Obtained by the preparation method according to any one of claims 1 to 9.